Get the Stockscreener App
27.16
5.15%
1.33
Pre-market:
29.23
2.07
+7.62%
Ideaya Biosciences Inc stock is traded at $27.16, with a volume of 1.64M.
It is up +5.15% in the last 24 hours and up +12.60% over the past month.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
See More
Previous Close:
$25.83
Open:
$25.88
24h Volume:
1.64M
Relative Volume:
1.60
Market Cap:
$2.38B
Revenue:
$23.38M
Net Income/Loss:
$-155.22M
P/E Ratio:
-12.40
EPS:
-2.19
Net Cash Flow:
$-134.36M
1W Performance:
+10.63%
1M Performance:
+12.60%
6M Performance:
+40.07%
1Y Performance:
-27.32%
1-Day Range:
$25.88
$27.18
1-Week Range:
$24.18
$27.18
52-Week Range:
$13.45
$37.99
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Name
Ideaya Biosciences Inc
Sector
Industry
Phone
650-443-6209
Address
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
27.16 | 2.26B | 23.38M | -155.22M | -134.36M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Initiated | Barclays | Overweight |
| Sep-04-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-22-25 | Initiated | TD Cowen | Buy |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Jun-26-25 | Initiated | Wells Fargo | Overweight |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Nov-05-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-15-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Mar-08-24 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | SVB Securities | Outperform |
| May-24-23 | Initiated | Goldman | Buy |
| Apr-24-23 | Upgrade | Stifel | Hold → Buy |
| Mar-23-23 | Initiated | Berenberg | Buy |
| Feb-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Dec-28-22 | Initiated | CapitalOne | Overweight |
| Oct-27-22 | Initiated | Citigroup | Buy |
| Aug-15-22 | Downgrade | Stifel | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-10-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Mar-11-21 | Initiated | Guggenheim | Buy |
| Oct-07-20 | Initiated | Wedbush | Outperform |
| Sep-01-20 | Initiated | Northland Capital | Outperform |
| Jul-13-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-06-20 | Initiated | H.C. Wainwright | Buy |
| Mar-13-20 | Initiated | ROTH Capital | Buy |
| Oct-17-19 | Initiated | Oppenheimer | Outperform |
| Sep-10-19 | Initiated | Robert W. Baird | Outperform |
| Jun-17-19 | Initiated | Citigroup | Buy |
| Jun-17-19 | Initiated | JP Morgan | Neutral |
| Jun-17-19 | Initiated | Jefferies | Buy |
View All
Ideaya Biosciences Inc Stock (IDYA) Latest News
Ideaya Biosciences stock price target raised to $45 at Citizens JMP - Investing.com
76% Tumor Shrinkage: IDEAYA's Breakthrough Eye Cancer Drug Could Prevent Blindness in Melanoma Patients - Stock Titan
Ideaya, Partner Say Small Cell Lung Cancer Phase 1 Trial Shows Strong Response Rate - MarketScreener
Is IDEAYA Biosciences Inc. stock a good dividend stockJuly 2025 Short Interest & Verified Technical Trade Signals - beatles.ru
Ideaya Biosciences Shares Jump Following $210 Million Licensing Deal with Servier - MSN
Ideaya and Hengrui report promising data for DLL3-targeted cancer drug - Investing.com
80% Cancer Response Rate: IDEAYA's First-in-Class Drug IDE849 Shows Promise in Hard-to-Treat Lung Cancer - Stock Titan
The week in pharma: action, reaction and insight – week to September 5 - The Pharma Letter
IDEAYA Biosciences Inc. Reversal Rally May Surprise BearsQuarterly Market Review & Free Real-Time Volume Trigger Notifications - beatles.ru
Ideaya Biosciences stock hits 52-week low at $21.02 - MSN
Real time alert setup for IDEAYA Biosciences Inc. performancePortfolio Risk Summary & Weekly Breakout Watchlists - Newser
Trend analysis for IDEAYA Biosciences Inc. this week2025 Technical Patterns & Fast Entry Momentum Alerts - Newser
How to forecast IDEAYA Biosciences Inc. trends using time seriesWeekly Risk Summary & AI Powered Market Trend Analysis - Newser
Can you recover from losses in IDEAYA Biosciences Inc.2025 Risk Factors & Long-Term Growth Portfolio Plans - Newser
Ideaya Biosciences gets coverage initiation at Barclays and Citizens - MSN
Using Python tools to backtest IDEAYA Biosciences Inc. strategiesEarnings Trend Report & Scalable Portfolio Growth Methods - Newser
Quantitative breakdown of IDEAYA Biosciences Inc. recent moveJuly 2025 Institutional & Verified Short-Term Plans - Newser
Real time breakdown of IDEAYA Biosciences Inc. stock performanceQuarterly Investment Review & AI Forecasted Stock Moves - Newser
Best data tools to analyze IDEAYA Biosciences Inc. stockWeekly Trend Report & Risk Adjusted Swing Trade Ideas - Newser
Measuring IDEAYA Biosciences Inc.’s beta against major indicesQuarterly Trade Review & Risk Controlled Daily Plans - Newser
IDEAYA Biosciences Inc. stock daily chart insightsTrade Entry Summary & Proven Capital Preservation Methods - Newser
Is IDEAYA Biosciences Inc. stock risky to hold nowJuly 2025 Chart Watch & Free Verified High Yield Trade Plans - خودرو بانک
Comparing IDEAYA Biosciences Inc. in custom built stock radarsDip Buying & Verified Momentum Stock Watchlist - Newser
IDEAYA enrolls first lung cancer patient in targeted therapy trial By Investing.com - Investing.com Nigeria
Will IDEAYA Biosciences Inc. continue its uptrendJuly 2025 Retail & AI Enhanced Trade Execution Alerts - Newser
Can IDEAYA Biosciences Inc. be recession proofPortfolio Value Summary & Smart Money Movement Tracker - خودرو بانک
Is IDEAYA Biosciences Inc.’s ROIC above industry averageJuly 2025 Recap & AI Based Buy and Sell Signals - خودرو بانک
Why IDEAYA Biosciences Inc. stock attracts strong analyst attentionJuly 2025 Catalysts & Safe Investment Capital Preservation Plans - Newser
Ideaya Biosciences stock initiated with Market Outperform rating by Citizens JMP - Investing.com Canada
What machine learning models say about IDEAYA Biosciences Inc.Market Performance Summary & Daily Momentum Trading Reports - Newser
IDEAYA Biosciences Rings the Opening Bell - Nasdaq
Ideaya submits IND for PRMT5 inhibitor - BioWorld MedTech
IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer - biospace.com
IDEAYA Biosciences: Barclays initiates coverage at Overweight, PT $40. - AInvest
IDEAYA enrolls first lung cancer patient in targeted therapy trial - Investing.com
IDEAYA Biosciences Expands Phase 1/2 Trial for IDE397 and Trodelvy Combination in MTAP-Deletion Non-Small Cell Lung Cancer. - AInvest
First Patient Dosed: Novel MAT2A Inhibitor + Trodelvy Combo Targets 20% of Lung Cancer Patients - Stock Titan
Barclays Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $40 - 富途牛牛
How high can IDEAYA Biosciences Inc. stock goJuly 2025 Summary & Fast Momentum Entry Tips - Newser
Regression analysis insights on IDEAYA Biosciences Inc. performanceJuly 2025 Sector Moves & Weekly Chart Analysis and Trade Guides - Newser
Is IDEAYA Biosciences Inc. trending in predictive chart modelsAnalyst Upgrade & Weekly High Return Forecasts - Newser
IDEAYA Biosciences: A High-Conviction Biotech Play with Precision Oncology Catalysts - AInvest
Transcript : IDEAYA Biosciences, Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-03-2025 09 - MarketScreener
Real time scanner hits for IDEAYA Biosciences Inc. explainedIndex Update & Technical Pattern Based Buy Signals - Newser
Is IDEAYA Biosciences Inc. gaining market shareWeekly Trend Summary & Stepwise Swing Trade Plans - خودرو بانک
How hedge fund analytics apply to IDEAYA Biosciences Inc. stockJuly 2025 Opening Moves & High Conviction Buy Zone Alerts - Newser
Ideaya Biosciences stock price target raised to $74 by JPMorgan - Investing.com Canada
A Quick Look at Today's Ratings for IDEAYA Biosciences(IDYA.US), With a Forecast Between $43 to $74 - 富途牛牛
IDEAYA Biosciences submits IND for new cancer drug IDE892 - Investing.com
IDEAYA Biosciences submits IND for new cancer drug IDE892 By Investing.com - Investing.com Australia
What high frequency data says about IDEAYA Biosciences Inc.Portfolio Value Summary & High Accuracy Trade Signal Alerts - Newser
Ideaya Biosciences Inc Stock (IDYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):